Skip to Content
Merck
  • Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.

Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.

The Journal of steroid biochemistry and molecular biology (2014-02-26)
Dong-Sheng Ming, Steven Pham, Subrata Deb, Mei Yieng Chin, Geetanjali Kharmate, Hans Adomat, Elham Hosseini Beheshti, Jennifer Locke, Emma Tomlinson Guns
ABSTRACT

Castration-resistant prostate cancer (CRPC) remains largely dependent on androgen receptor (AR). Residual tissue androgens are consistently detected within CRPC tumors and play a critical role in facilitating AR-mediated signaling pathways which lead to disease progression. Testosterone and dihydrotestosterone (DHT) are the major androgens detected in tumors. They are produced through three biosynthesis pathways: Δ(4), Δ(5), and backdoor pathways. Both androgens bind to and stimulate AR activation. The current study investigates the effects of pomegranate extracts (POM) and their ability to inhibit androgen biosynthesis using PCa cell lines (22RV1 and LNCaP) in vitro as well as the PTEN knockout mouse model representing prostate cancer. Steroids were extracted using ethyl acetate or solid phase extraction, and then analyzed by UPLC/MS/MS. The results showed that POM (0-12μg/mL) reduced the production of testosterone, DHT, DHEA, androstenedione, androsterone, and pregnenolone in both cell lines. In addition our in vivo data supports this observation with a reduction in serum steroids determined after 20 weeks of POM treatment (0.17 g/L in drinking water). In accordance with these results, Western blotting of cell lysates and tPSA analysis determined that PSA was significantly decreased by the treatment of POM. Interestingly, AKR1C3 and AR levels were shown to be increased in both cell lines, perhaps as a negative feedback effect in response to steroid inhibition. Overall, these results provide mechanistic evidence to support the rationale for recent clinical reports describing efficacy of POM in CRPC patients.

MATERIALS
Product Number
Brand
Product Description

Progesterone, European Pharmacopoeia (EP) Reference Standard
Supelco
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Hydroxylamine hydrochloride, ACS reagent, 98.0%
Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard
Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Formic acid, ACS reagent, ≥88%
Sigma-Aldrich
Hydroxylamine hydrochloride, puriss. p.a., ACS reagent, ≥99.0% (RT)
Sigma-Aldrich
5-Pregnen-3β-ol-20-one, ≥98%
USP
Progesterone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Formic acid solution, BioUltra, 1.0 M in H2O
Sigma-Aldrich
trans-Dehydroandrosterone, ≥99%
Sigma-Aldrich
Hydroxylamine hydrochloride, 99.999% trace metals basis
Supelco
Progesterone, VETRANAL®, analytical standard
Sigma-Aldrich
Hydroxylamine hydrochloride, 99.995% trace metals basis
Supelco
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethyl acetate, ReagentPlus®, ≥99.8%
Sigma-Aldrich
Ethyl acetate, anhydrous, 99.8%
Supelco
Ethyl acetate, analytical standard
Sigma-Aldrich
Ethyl acetate, natural, ≥99%, FCC, FG
Sigma-Aldrich
Formic acid, ≥95%, FCC, FG
Sigma-Aldrich
Ethyl acetate, ≥99%, FCC, FG
Sigma-Aldrich
Formic acid, ACS reagent, ≥96%
Sigma-Aldrich
Ethyl acetate, ACS reagent, ≥99.5%
Sigma-Aldrich
Formic acid, puriss., meets analytical specifications of DAC, FCC, 98.0-100%
Sigma-Aldrich
Ethyl acetate, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99.5% (GC)
Sigma-Aldrich
Formic acid, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥98%
Sigma-Aldrich
Ethyl acetate, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
Ethyl acetate